<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yuita H</submitter><funding>HHS | National Institutes of Health</funding><funding>MEXT | Japan Society for the Promotion of Science</funding><funding>NCRR NIH HHS</funding><funding>University of California Institute for Mexico and the United States</funding><funding>Japan Agency for Medical Research and Development</funding><funding>Ministry of Education, Culture, Sports, Science and Technology</funding><funding>NCI NIH HHS</funding><funding>National Research Foundation of Korea</funding><funding>NIH HHS</funding><funding>Ulsan National Institute of Science and Technology</funding><pagination>e2214824120</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9963276</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>120(6)</volume><pubmed_abstract>The three mammalian TET dioxygenases oxidize the methyl group of 5-methylcytosine in DNA, and the oxidized methylcytosines are essential intermediates in all known pathways of DNA demethylation. To define the in vivo consequences of complete TET deficiency, we inducibly deleted all three &lt;i>Tet&lt;/i> genes in the mouse genome. &lt;i>Tet1/2/3-inducible TKO&lt;/i> (&lt;i>iTKO&lt;/i>) mice succumbed to acute myeloid leukemia (AML) by 4 to 5 wk. Single-cell RNA sequencing of &lt;i>Tet iTKO&lt;/i> bone marrow cells revealed the appearance of new myeloid cell populations characterized by a striking increase in expression of all members of the &lt;i>stefin/cystatin&lt;/i> gene cluster on mouse chromosome 16. In patients with AML, high &lt;i>stefin/cystatin&lt;/i> gene expression correlates with poor clinical outcomes. Increased</pubmed_abstract><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><pubmed_title>Inducible disruption of &lt;i>Tet&lt;/i> genes results in myeloid malignancy, readthrough transcription, and a heterochromatin-to-euchromatin switch.</pubmed_title><pmcid>PMC9963276</pmcid><funding_grant_id>2018R1A6A1A03025810</funding_grant_id><funding_grant_id>JP20gm1210003</funding_grant_id><funding_grant_id>S10OD016262</funding_grant_id><funding_grant_id>JP19H05650</funding_grant_id><funding_grant_id>1.180075.01</funding_grant_id><funding_grant_id>1.220023.01</funding_grant_id><funding_grant_id>(A) 20KK0351</funding_grant_id><funding_grant_id>R35 CA210043</funding_grant_id><funding_grant_id>2019R1F1A1063340</funding_grant_id><funding_grant_id>UC MEXUS-CONACYT Fellowship</funding_grant_id><funding_grant_id>S10 OD016262</funding_grant_id><funding_grant_id>S10 RR027366</funding_grant_id><funding_grant_id>S10RR027366</funding_grant_id><pubmed_authors>Rao A</pubmed_authors><pubmed_authors>Ko M</pubmed_authors><pubmed_authors>Jeong H</pubmed_authors><pubmed_authors>Cheng AX</pubmed_authors><pubmed_authors>Nakayama T</pubmed_authors><pubmed_authors>An J</pubmed_authors><pubmed_authors>Lopez-Moyado IF</pubmed_authors><pubmed_authors>Yuita H</pubmed_authors><pubmed_authors>Onodera A</pubmed_authors><pubmed_authors>Scott-Browne J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Inducible disruption of &lt;i>Tet&lt;/i> genes results in myeloid malignancy, readthrough transcription, and a heterochromatin-to-euchromatin switch.</name><description>The three mammalian TET dioxygenases oxidize the methyl group of 5-methylcytosine in DNA, and the oxidized methylcytosines are essential intermediates in all known pathways of DNA demethylation. To define the in vivo consequences of complete TET deficiency, we inducibly deleted all three &lt;i>Tet&lt;/i> genes in the mouse genome. &lt;i>Tet1/2/3-inducible TKO&lt;/i> (&lt;i>iTKO&lt;/i>) mice succumbed to acute myeloid leukemia (AML) by 4 to 5 wk. Single-cell RNA sequencing of &lt;i>Tet iTKO&lt;/i> bone marrow cells revealed the appearance of new myeloid cell populations characterized by a striking increase in expression of all members of the &lt;i>stefin/cystatin&lt;/i> gene cluster on mouse chromosome 16. In patients with AML, high &lt;i>stefin/cystatin&lt;/i> gene expression correlates with poor clinical outcomes. Increased</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2026-03-18T14:08:16.315Z</modification><creation>2025-04-04T20:04:50.913Z</creation></dates><accession>S-EPMC9963276</accession><cross_references><pubmed>37406303</pubmed><doi>10.1073/pnas.2214824120</doi></cross_references></HashMap>